Belite Bio, INC

Hao-Yuan Chuang, Chief Financial Officer and a Director of Belite Bio, Inc, reported a transaction in 5,000 shares of common stock on October 29, 2026.

Yu-Hsin Lin, Chief Executive Officer and a Director of Belite Bio, Inc, reported a transaction in 5,000 shares of common stock on October 29, 2026.

Wan-Shan Chen, a Director of Belite Bio, Inc, reported multiple transactions in common stock on September 24, 2026.

Hendrik Peter Scholl, Chief Medical Officer of Belite Bio, Inc, sold 500 shares of common stock on October 1, 2026.

Yu-Hsin Lin, Chief Executive Officer and a Director of Belite Bio, Inc, sold 100,435 shares of common stock on September 4, 2026.

Hao-Yuan Chuang, Chief Financial Officer and a Director of Belite Bio, Inc, sold 67,395 shares of common stock on September 4, 2026.

Yu-Hsin Lin, CEO and Chairman of Belite Bio, Inc., has filed a Schedule 13G, reporting beneficial ownership of 3.1% of the company's ordinary shares as of March 31, 2026.

Darwin Global Management, Ltd., along with its Master Fund and CIO Dr. Abhishek Trehan, has disclosed a beneficial ownership of 7.0% in Belite Bio, Inc.'s ordinary shares.

Yu-Hsin Lin, CEO and Chairman of BELITE BIO, INC., has reported a beneficial ownership of 7.1% of the company's ordinary shares as of December 31, 2024, through a Schedule 13G filing.

Lin Bioscience International Ltd. has reported a beneficial ownership of 53.7% in Belite Bio, Inc., making it a majority shareholder.